Plain-English translation of NCT05570149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing eptinezumab, a medication given by IV infusion every three months to help prevent migraines. Researchers want to see how well this treatment works in real-world conditions—meaning regular medical offices and headache clinics—rather than just in controlled research settings. The study will follow 500 patients with either frequent episodic migraines or chronic migraines for 12 months.
While this medication has worked well in research trials, researchers want to understand how it performs when used in everyday clinical practice with a broader range of patients. This real-world evidence helps doctors and patients know what to expect outside of strict research conditions.
You likely qualify if…
You likely don't qualify if…
You would receive the medication by IV infusion at a participating headache center, with doses given every three months over the 12-month study period. Your doctor may start you with a lower dose (100 mg) and adjust to a higher dose (300 mg) if needed based on how you respond. Throughout the year, you would be monitored for how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Enrollment target
~500 participants
Started
January 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Piero Barbanti, MD, PhD
IRCCS San Raffaele Roma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.